Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SesZen-Bio is a bio-optimized, plant-based biotin extract derived from the leaves of *Sesbania grandiflora* (the hummingbird tree). Developed by Nutriventia, it is marketed as a 100% natural, organic alternative to synthetic biotin (Vitamin B7). The drug functions as an essential cofactor for several carboxylase enzymes, which are critical for fatty acid synthesis, gluconeogenesis, and the metabolism of branched-chain amino acids. By facilitating these metabolic processes, SesZen-Bio supports the production of keratin, thereby promoting the structural integrity and growth of hair, skin, and nails. It is specifically formulated to maintain the natural plant matrix, which the developer suggests may enhance the bioavailability and metabolic utility of the biotin compared to its synthetic counterparts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SesZen-Bio.